Morphologic, genetic, immunohistochemical, and clinical data of the 6 MMML cases carrying 11q-gain/loss pattern selected for GEP analysis (cohort 3)
| Case no. . | Age, sex . | Diagnosis . | Location . | FISH . | . | Immunohistochemistry . | Mutations . | . | . | . | . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MYC break . | BCL6 break . | t(14;18) . | MYC . | CD20 . | CD10 . | CD5 . | BCL2 . | BCL6 . | MUM1 . | Ki67 . | EBER . | IGHV . | BCL6 . | MYC . | GEP ABC/GCB . | Molecular diag . | PAP diag‡ . | Outcome, follow-up . | ||||
| MPI-078 | 8, male | Centroblastic, DLBCL | LN(c) | – | – | – | + | + | – | – | + | + | 95 | – | mut | mut | wt | GCB | mBL | mind-L | In complete remission, alive, 119 mo | |
| MPI-086¶ | 14, male | High grade B-cell lymphoma | LN(c) | – | – | – | + | + | + | – | – | + | – | 90 | – | mut | mut | wt | GCB | mBL | BL-PAP | In complete remission, alive, 161 mo |
| MPI-148* | 26, male | Atypical BL | extranodal | – | – | – | – | + | – | – | + | – | 90 | – | mut | mut | wt | GCB | intermediate | BL-PAP | In complete remission, alive, 163 mo | |
| MPI-315 | 49, female | Centroblastic, DLBCL | intestine | – | – | – | + | – | – | + | + | + | 90 | – | mut | na | na | GCB | intermediate | PAP-1 | In complete remission, alive, 106 mo | |
| MPI-382¶ | 24, male | Centroblastic, DLBCL | LN | – | – | – | + | + | na | na | + | na | 90 | – | mut | na | na | GCB | mBL | BL-PAP | In complete remission, alive, 91 mo | |
| MPI-626† | 7, male | Malignant B-cell lymphoma | LN(c) | – | – | – | + | + | – | – | + | – | 90 | – | mut | na | wt | GCB | intermediate | mind-L | In remission, alive, 62 mo | |
| Case no. . | Age, sex . | Diagnosis . | Location . | FISH . | . | Immunohistochemistry . | Mutations . | . | . | . | . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MYC break . | BCL6 break . | t(14;18) . | MYC . | CD20 . | CD10 . | CD5 . | BCL2 . | BCL6 . | MUM1 . | Ki67 . | EBER . | IGHV . | BCL6 . | MYC . | GEP ABC/GCB . | Molecular diag . | PAP diag‡ . | Outcome, follow-up . | ||||
| MPI-078 | 8, male | Centroblastic, DLBCL | LN(c) | – | – | – | + | + | – | – | + | + | 95 | – | mut | mut | wt | GCB | mBL | mind-L | In complete remission, alive, 119 mo | |
| MPI-086¶ | 14, male | High grade B-cell lymphoma | LN(c) | – | – | – | + | + | + | – | – | + | – | 90 | – | mut | mut | wt | GCB | mBL | BL-PAP | In complete remission, alive, 161 mo |
| MPI-148* | 26, male | Atypical BL | extranodal | – | – | – | – | + | – | – | + | – | 90 | – | mut | mut | wt | GCB | intermediate | BL-PAP | In complete remission, alive, 163 mo | |
| MPI-315 | 49, female | Centroblastic, DLBCL | intestine | – | – | – | + | – | – | + | + | + | 90 | – | mut | na | na | GCB | intermediate | PAP-1 | In complete remission, alive, 106 mo | |
| MPI-382¶ | 24, male | Centroblastic, DLBCL | LN | – | – | – | + | + | na | na | + | na | 90 | – | mut | na | na | GCB | mBL | BL-PAP | In complete remission, alive, 91 mo | |
| MPI-626† | 7, male | Malignant B-cell lymphoma | LN(c) | – | – | – | + | + | – | – | + | – | 90 | – | mut | na | wt | GCB | intermediate | mind-L | In remission, alive, 62 mo | |
−, negative; +, positive; ABC, activated B cell; c, cervical; diag, diagnosis; EGER, Epstein-Barr–encoded RNA test; GCB, germinal center B cell; GEP, gene expression profiling; LN, lymph node; mind-L, molecularly individual lymphoma; mut, mutated; na, not available; PAP, pathway activation pattern algorithm; wt, wild-type.
This case presented the following karyotype: 46,XY,t(7;18)(q32;q21),inv dup(11)(q23q13),add(15)(q22),inv(16)(q11q24).
This case corresponds to case 1 from cohort 2 and was investigated using SNP and CGH-array platforms.
Molecular diagnoses described in Hummel et al and Bentink et al, respectively.7,12
These two cases belong to cohort 1. Lymphoma samples were scored positive if >25% of the tumor cells stained positive except for MYC, where the cutoff was established in 40%.